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Abstract-Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) 
frequently includes use of immunosuppressive agents. Controlled treatment trials 
demonstrating efficacy are available only for prednisone and therapeutic plasma 
exchange (TPE). When these fail to achieve lasting clinical improvement after reduction 
or cessation of therapy, subsequent regimens are empiric, often leading to prolonged 
immunosuppression. It is not possible to predict who will respond to which agent and 
when. Administered individually, immunosuppressive agents may pose an acceptable 
risk, but cumulative effects of multiple agents in refractory patients may suppress the 
immune system and contribute to increased morbidity and mortality. Treatment 
difficulties with refractory CIDP patients have not been emphasized, and long-term 
effects of immunosuppression have focused on the risk of malignancy. In reviewing our 
clinical experience treating over 100 CIDP patients we identified approximately 20 
patients who could be considered refractory to multiple immunosuppressive therapies 
and dependent upon long-term intermittent TPE. Two of these patients exemplify the 
morbidity associated with CIDP and its associated treatment. Our review of the clinical 
course of these patients raised issues about the use of multiple immunosuppressive 
agents, long-term goals, and long-term prognosis in CIDP. 
Chronic inflammatory polyradiculoneuropathy CIDP Treatment of polyneuro- 
pathy Long-term immunosuppression 
INTRODUCTION 
Chronic inflammatory demyelinating polyneu- 
ropathy (CIDP) may follow a progressive or 
relapsing clinical course [l]. Treatment of 
CIDP is based on altering the immune system 
[l, 21. The experience of our Neuromuscular 
Clinic in treating over 100 CIDP patients during 
the past decade is similar to that reported from 
other neuromuscular centers in that (1) the 
majority of patients respond satisfactorily to 
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a single agent or combination treatment 
regimen of therapeutic plasma exchange (TPE) 
and corticosteroids; (2) a substantial percentage 
of patients respond less well to corticosteroids 
and experience relapses which require treatment 
with immunosuppressive agents; and (3) a 
small group of patients are refractory to 
multiple agents and become bed or wheel- 
chair bound, and may die from the disease 
[l, 3,4]. For the latter two groups of CIDP 
patients, the choice of subsequent treatment 
regimens become problematic [ 1,2]. There 
are few controlled trials of single [5-71 
and multiple agents [8], and the choice of 
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In reviews of therapeutic response in CIDP 
patients, treatment failures and circumstances 
surrounding patient morbidity and mortality 
(other than from respiratory failure) are rarely 
reported [l, 3,4]. From our clinical experience 
in treating refractory CIDP patients, two 
patients stand out because of similar courses. 
Both were dependent upon TPE despite receiv- 
ing multiple immunosuppressive therapies given 
in an attempt to prolong remission and reduce 
disability and both had similar medical compli- 
cations occurring late in their treatment. The 
clinical experience with these two patients raises 
issues about use of multiple immunosuppressive 
agents, long-term goals, and long-term progno- 
sis in severe CIDP. 
CASE PRESENTATIONS, TREATMENT 
RESPONSES, AND POST-MORTEM FINDINGS 
Both patients were men in good health and 
with no pertinent past medical, family and toxic 
exposure histories, except patient A had mild 
non-insulin dependent diabetes mellitus diag- 
nosed and treated with chlorpropamide 6 
months after onset of neurologic symptoms. 
Medical examinations, laboratory blood stud- 
ies, skeletal X-ray surveys, and bone marrow 
biopsies were normal. Neither had anti-myelin 
associated antibody activity. Motor nerve con- 
duction studies fulfilled criteria suggestive of 
acquired primary demyelination [9]. Needle 
electromyography revealed chronic denerva- 
tion. Late in the illness, patient B had only 1 or 2 
voluntary motor units in intrinsic hand muscles. 
TPEs were performed on continuous flow 
machines. Remission was induced with a course 
of 5 TPE treatments performed every other day, 
and remission was maintained by single ex- 
changes at intervals from twice weekly to once 
every 3 weeks. 
Patient A presented at age 58 with distal 
numbness and weakness and over 6 months 
became bedridden (MRC grade 3 + ; functional 
scale grade 4, see Fig. 1). An IgG kappa gam- 
mopathy was found. His initial response to 
combined oral prednisone and a course of TPE 
(schedule and dosages, see Table 1 and Fig. 1) 
was rapid, with improved limb strength within 
days, ambulation with a cane by 2 months, and 
bicycle riding by 5 months. Exacerbations which 
affected ambulation often occurred precipi- 
tously over l-3 days, but response was prompt 
and reliable following 5 TPEs. Sustained im- 
provement without TPE was not accomplished 
and he remained dependent upon periodic 
weekly or twice weekly TPE despite receiving 
cyclophosphamide, TLI, and melphalan. In- 
creasing the interval between TPE treatments 
resulted in deterioration on each occasion it was 
attempted. 
At final hospitalization for unexplained and 
worsening jaundice, patient A was ambulatory, 
but dependent upon weekly TPEs. Hepatitis A 
and B markers were normal, and there was no 
evidence of biliary obstruction. He developed 
thrombocytopenia and a coagulopathy which 
necessitated a reduction in TPE frequency. He 
became weaker, developed mild adult respirat- 
ory distress syndrome, and temporarily required 
Table 1. Summary of immunosuppressive therapy (see also Fig. 1) 
Treatment Patient A Patient B 












Total lymphoid irradiation 
215 
3/83-8/81 







100-200 mg QD 
6/84-l l/84 
(leukopenia, count 2000) 
12mg QD x 4 doses 
3187, 4187, 5187 
Mantle: 1950 rad 




10mg QOD-6Omg QD 
4/83-12187 
1 g x 3 doses 
3187 
150-200 mg QD 
9183-2184 
(leukopenia, count 2000) 
llmgQDx4dose.s 
6187, 7187, 8187 
Mantle: 2160 rad 
Inverted Y: 120 rad 
1 l/86-12/86 
(leukopenia, count 2000) 
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Fig. I. Clinical course and treatment schedules. Upper trace: functional grading scale of strength*. Second 
trace: time and duration of immunosuppressive drugs (see Table for dosages). Third trace: averaged daily 
prednisone dosage. Lower trace: number of TPE treatments per month. (A) Patient A and (B) patient 
8. *Functional grading scale: O-healthy; l-minor signs or symptoms; 2-able to walk 5 m without a 
walker or equivalent support; 3-able to walk 5 m with a walker or support; Abed or chairbound (unable 
to walk 5 m with a walker or support); 5-requires assisted ventilation; 6-dead. 
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ventilatory support. Pneumonia developed and 
he died at age 63, 5$ years after onset of 
neurologic symptoms. Post-mortem examin- 
ation revealed disseminated aspergillosis and 
candidemia, with cytomegalic virus inclusions in 
lung and liver. The hepatobiliary system was 
unremarkable. The liver had confluent central 
zone necrosis without evidence of lymphocytic 
infiltration or fibrosis or alterations of the portal 
system. No amyloid was detected. 
Patient B presented at age 55 with acral 
numbness and weakness which progressed over 
2: years (MRC grade 4; functional grade 2, see 
Fig. 1). An IgM lambda gammopathy was 
discovered. There was no response to 3 months 
of oral prednisone (schedule and dosages, see 
Table 1 and Fig. l), but he responded promptly 
to a course of 5 TPEs. This was short lived 
and his condition deteriorated until he was 
bedbound. He slowly improved over many 
months on combined prednisone and azathio- 
prine therapy to the point of cautious unaided 
walking. An abrupt relapse associated with 
a viral-like illness caused him to become 
wheelchair-bound. He never improved despite 
use of azathioprine, TLI, and melphalan. Main- 
tenance of limited strength remained dependent 
upon frequent TPEs. 
His final admission was for bloody diarrhea. 
Adult respiratory distress syndrome developed 
and ventilator support was required. He 
developed coagulase negative staphylococcus 
bacteremia and candidemia. He became hypo- 
tensive and comatose, and died at age 63, 7f 
years after onset of neurologic symptoms. Post- 
mortem findings included mucosal infarcts 
of the large bowel, bacterial pneumonitis, and 
cytomegalic viral inclusions in the lungs. No 
adenopathy, marrow infiltrates, or amyloid was 
found. 
DISCUSSION 
The relapsing or progressive forms of CIDP 
frequently require protracted treatment. Thera- 
peutic modalities demonstrated to be effective in 
controlled trials include TPE [6] and prednisone 
[5]. Sustained remission with TPE alone is rare 
and concurrent use of corticosteroids is usually 
required [6]. Prolonged treatment with pred- 
nisone is associated with troublesome side 
effects [l, 10, 111. For some patients, high dose 
prednisone may not be effective [14], and under 
these circumstances immunosuppressive agents 
are commonly used [2]. 
The choice of subsequent therapy becomes 
uncertain, and without controlled studies, the 
choice is guided only by case reports. Immuno- 
suppressive agents reported effective at time of 
treatment of our two patients, or subsequently, 
included azathioprine [ 121, cyclophosphamide 
[2], melphalan [13], polyinosinic-polycytidylic 
acid [14], TLI [15], cyclosporin [16], and i.v. 
gammaglobulin [7, 171. 
Our patients were examples of patients with 
relapsing and refractory CIDP who had severe 
disability and common side effects of pred- 
nisone. For each, azathioprine was chosen [12] 
but was not tolerated; and patient A had 
a systemic reaction with the first doses [18], and 
patient B had leukopenia after 5 months, which 
subsequently resolved. Cyclophosphamide was 
tolerated by patient A but was discontinued 
because of transient leukopenia. TLI was ad- 
ministered because of continued weakness and a 
report of 4 patients with refractory CIDP who 
showed improvement 3 months after treatment 
with TLI with no major side effects [15]. Radi- 
ation therapy was well tolerated with only mild 
and transient leukopenia in patient B, but there 
were no remissions during follow up periods of 
10-24 months. Although there was no evidence 
for plasma cell malignancy, melphalan was 
given because of a good response in refractory 
dysproteinemic polyneuropathy [ 131. Neither 
patient lived long enough to reliably assess 
drug response. Melphalan has been associated 
with pulmonary fibrosis [19], but pulmonary 
difficulties began after melphalan was discon- 
tinued, and there was no pathologic evidence 
for fibrosis or atypical alveolar cells. 
Both of our patients had a monoclonal 
gammopathy of uncertain significance (MGUS). 
It is not clear if CIDP with MGUS represents 
a separate disorder or is part of a spectrum 
of CIDP [20]. The presence of a MGUS in 
CIDP is common, occurring in up to 30% of 
patients [21], and our patients followed a 
clinical course typical for CIDP before and 
early-on after treatment was initiated. Without 
evidence for an underlying tumor at post- 
mortem examination we feel the MGUS did not 
make the clinical course of our two patients 
unique. 
As the therapeutic regimen is extended, pro- 
longed immunosuppression becomes a concern. 
Most reviews of complications of long-term 
immunosuppressive therapy focus on increased 
risk of malignancy [22,23]. There was no 
evidence of tumor in our patients. However, 
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both patients at post-mortem examination had 
disseminated cytomegalic inclusion bodies 
and evidence of multiple fungal and bacterial 
infections suggesting marked impairment of 
immunologic function. Consideration must 
be given to accumulated effects of multiple 
immunosuppressive agents to account for 
marked immunosuppression. Of the agents 
used, TLI induces long lasting suppression of 
cell mediated immunity [24]. Long-term side 
effects of TLI alone [25], or with multiple 
immunosuppressive therapies, have been dis- 
cussed [26]. Conditions and circumstances 
which contribute to morbidity and mortality 
under these circumstances include bacterial and 
viral infections, greater degree of physical dis- 
ability, and patient age greater than 65 years 
[25,27]. 
The difficult clinical issue is the CIDP patient 
who never responds to treatment or who 
responds temporarily but relapses frequently 
despite vigorous treatment with multiple 
immunosuppressive agents. There are no obvi- 
ous means of early identification of such 
patients. Continued efforts with more immuno- 
suppressive agents must be tempered by recog- 
nition of possible cumulative effects on the 
immune system. The pressures to treat refrac- 
tory CIDP patients with vigorous immuno- 
suppression are different than the pressures to 
treat other patients groups, such as transplant 
patients. Accordingly, other factors in CIDP 
patients, such as the extent of clinical deficits 
(profound sensory loss and weakness), duration 
of illness, and advanced age must be considered 
and should influence choice of drugs and dur- 
ation of trials [6]. In particular, in patients with 
evidence of substantial axonal loss on electro- 
diagnostic studies 161, treatment response is 
difficult to evaluate because it may be delayed 
by months. In addition, the reinnervation ca- 
pacity in older individuals may be limited and 
partially satiated by age-related loss of motor 
neurons or axons [28,29]. In such patients, 
multiple therapeutic agents may be used and 
abandoned or supplemented with other agents 
before it would have been possible to judge their 
effectiveness. Attempts to find agents which will 
improve patient function and induce permanent 
remission are reasonable goals. However, recog- 
nition early on that patients who possess some 
of the factors listed above may do better and 
have fewer side effects with long term, periodic 
temporizing therapies such as TPE and i.v. 
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